Cidara Therapeutics jumps after accelerating late-stage trial for influenza therapy

Cidara Therapeutics

24/09/2025 17:29

** Shares of drugmaker Cidara Therapeutics CDTX.O rise 17.9% to over a 5-year high of $87.25

** Company says it has accelerated the late-stage study of its experimental influenza therapy, CD388, by six months

** Following FDA feedback, the study will now include healthy adults over 65, along with people over 12 years of age who have high-risk conditions or weakened immune system - CDTX

** In the late-stage trial, the company will test the safety and effectiveness of a single 450 mg dose of CD388, given as a shot under the skin at the start of flu season

** RBC expects CD388 to move quickly through development and believes it could generate around $3.7 billion in global sales in the future

** RBC added that the FDA indicated one Phase III trial would be sufficient to support the application, with data from the earlier Phase IIb trial aiding the process, alleviating concerns some investors had about potential delays

** Including session moves, stock has more than tripled YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))